Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 61, Issue 1, Pages 113-123Publisher
IOS PRESS
DOI: 10.3233/JAD-170592
Keywords
ADAM10 protein; aging; Alzheimer's disease; biomarkers; microRNAs
Categories
Funding
- Sao Paulo Research Foundation - FAPESP [2012/08654-7, 2013/06879-4]
- AIRAlzh Onlus-COOP Italia
Ask authors/readers for more resources
ADAM10 is the alpha-secretase that cleaves amyloid-beta protein precursor in the non-amyloidogenic pathway in Alzheimer's disease (AD) and is known to be regulated by different microRNAs (miRNAs), which are post-transcriptional regulators related to several biological and pathological processes, including AD. Here we proposed to explore and validate miRNAs that have direct or indirect relations to the AD pathophysiology and ADAM10 gene. Approximately 700 miRNAs were analyzed and 21 differentially expressedmiRNAs were validated in a sample of 21ADsubjects and 17 cognitively healthy matched controls. SH-SY5Y cells were transfected with miR-144-5p, miR-221, and miR-374 mimics and inhibitors, and ADAM10 protein levels were evaluated. miR-144-5p, miR-221, and miR-374 were downregulated in AD. The overexpression of miR-221 in SH-SY5Y cells resulted in ADAM10 reduction and its inhibition in ADAM10 increased. These findings show that miR-221 can be a new potential therapeutic target for increasing ADAM10 levels in AD. In addition, these results can contribute to the better understanding of ADAM10 post-transcriptional regulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available